Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD‐1 inhibitors (T‐L‐P) versus TACE...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Wei‐Jun Wang, Zong‐Han Liu, Kang Wang, Hong‐Ming Yu, Yu‐Qiang Cheng, Yan‐Jun Xiang, Jin‐Kai Feng, Li‐Ping Zhou, Hong‐Kun Zhou, Wei‐Wei Pan, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-05-01
Serija:	Cancer Medicine
Teme:	combination therapy hepatocellular carcinoma (HCC) lenvatinib programmed death‐1 recurrent transarterial chemoembolization (TACE)
Online dostop:	https://doi.org/10.1002/cam4.5880
Oznake:	Označite Brez oznak, prvi označite!